Genetically Engineered Light‐Responsive In Situ Hydrogels for Immunomodulation and Multimodal Therapy in Metastatic Triple‐Negative Breast Cancer
Advanced Science · 2026
DOI: 10.1002/advs.202512355 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Xinchen Shen und 11 weiteren Autor:innen. Beteiligte Einrichtung: The Zhejiang University-University of Edinburgh Institute, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, 310058, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Hydrogels, Immunomodulation. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province.
Abstract (Originalsprache)
Triple‐negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer, known for its early onset, strong metastatic tendencies, and poor prognosis. Conventional treatments, including chemotherapy and immunotherapy, often face challenges such as limited efficacy, adverse side effects, and high recurrence rates. To address these limitations, a family of tri‐block chimeric proteins, cysteine‐tagged silk‐elastin‐like proteins (cSELPs), is designed to form responsive in situ hydrogels for treating late‐stage and metastatic TNBC. These cSELPs are de novo designed to integrate multiple functional protein motifs, including a photothermal agent binding motif, silk‐inspired crosslinking motifs, and elastin‐like thermo‐responsive motifs. This unique sequence design enables the cSELP hydrogels to exhibit in situ gelation, photothermal responsive release of chemotherapeutic agent doxorubicin and immune checkpoint inhibitor anti‐PD‐L1, and antibacterial properties, leading to effective tumor microenvironment remodeling. By promoting immunogenic cell death and stimulating immune activation, this approach converts immunosuppressive “cold” tumors into immunologically active “hot” tumors. The cSELP hydrogel system demonstrates potent therapeutic efficacy against both primary and metastatic TNBC while maintaining excellent biocompatibility and long‐term safety. This protein material platform offers an innovative strategy to reshape the tumor microenvironment and combine multimodal treatments into a single biocompatible system, highlighting its potential for clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Zhejiang University-University of Edinburgh Institute, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, 310058, China.
- Deanery of Biomedical Sciences, Edinburgh Medical School, College of Medicine and Veterinary Medicine, The University of Edinburgh, Edinburgh, EH89AG, UK.
- Department of Cardiology of the Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, 310058, China.
- Department of Orthopedics of the Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, 310058, China.
- Dr. Li Dak Sum & Yip Yio Chin Center for Stem Cells and Regenerative Medicine, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, 310058, China.
- State Key Laboratory of Biobased Transportation Fuel Technology, Zhejiang University, Hangzhou, 310027, China.
ORCID-Profile: Xinchen Shen, Junhan Ou, Kaiyue Zhang, Wenwen Huang
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province
Zitieren
APA
Shen, X., Zhang, J., Ou, J., Bai, Z., Liu, T., Zhang, K., Zhu, K., Wang, J. Q., Wang, C., Zhang, Q., Lu, L., & Huang, W. (2026). Genetically Engineered Light‐Responsive In Situ Hydrogels for Immunomodulation and Multimodal Therapy in Metastatic Triple‐Negative Breast Cancer. Advanced Science. https://doi.org/10.1002/advs.202512355
Vancouver
Shen X, Zhang J, Ou J, Bai Z, Liu T, Zhang K, et al. Genetically Engineered Light‐Responsive In Situ Hydrogels for Immunomodulation and Multimodal Therapy in Metastatic Triple‐Negative Breast Cancer. Advanced Science. 2026. doi:10.1002/advs.202512355
BibTeX
@article{Shen2026,
author = {Shen, Xinchen and Zhang, Jiajia and Ou, Junhan and Bai, Ziheng and Liu, Tongyan and Zhang, Kaiyue and Zhu, Kaixiang and Wang, James Q and Wang, Chaochen and Zhang, Qianting and Lu, Linrong and Huang, Wenwen},
title = {Genetically Engineered Light‐Responsive In Situ Hydrogels for Immunomodulation and Multimodal Therapy in Metastatic Triple‐Negative Breast Cancer},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202512355}
}
EUVIMED